Technical Analysis for ARDX - Ardelyx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 2.71% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.81% | |
| Wide Bands | Range Expansion | -0.81% | |
| Oversold Stochastic | Weakness | -0.81% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.01% | |
| Stochastic Buy Signal | Bullish | -1.01% | |
| Calm After Storm | Range Contraction | -1.01% | |
| Lower Bollinger Band Walk | Weakness | -1.01% | |
| Wide Bands | Range Expansion | -1.01% |
| Alert | Time |
|---|---|
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
| Possible Inside Day | about 17 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Up 1% | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
Ardelyx, Inc. Description
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Phosphates Gastrointestinal Kidney Disease Metabolic Disease Chronic Kidney Disease End Stage Renal Disease Renal Disease Stage Renal Disease Constipation Irritable Bowel Syndrome Molecule Therapeutics Rockwell Medical Hyperphosphatemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.13 |
| 52 Week Low | 4.06 |
| Average Volume | 4,122,299 |
| 200-Day Moving Average | 6.73 |
| 50-Day Moving Average | 5.88 |
| 20-Day Moving Average | 5.46 |
| 10-Day Moving Average | 4.98 |
| Average True Range | 0.39 |
| RSI (14) | 40.83 |
| ADX | 22.54 |
| +DI | 17.46 |
| -DI | 27.94 |
| Chandelier Exit (Long, 3 ATRs) | 5.36 |
| Chandelier Exit (Short, 3 ATRs) | 5.51 |
| Upper Bollinger Bands | 6.70 |
| Lower Bollinger Band | 4.23 |
| Percent B (%b) | 0.28 |
| BandWidth | 45.14 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.26 |
| MACD Histogram | -0.0611 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.34 | ||||
| Resistance 3 (R3) | 5.31 | 5.13 | 5.27 | ||
| Resistance 2 (R2) | 5.13 | 5.03 | 5.15 | 5.25 | |
| Resistance 1 (R1) | 5.03 | 4.96 | 5.08 | 5.06 | 5.22 |
| Pivot Point | 4.85 | 4.85 | 4.88 | 4.87 | 4.85 |
| Support 1 (S1) | 4.75 | 4.75 | 4.80 | 4.78 | 4.62 |
| Support 2 (S2) | 4.57 | 4.68 | 4.59 | 4.59 | |
| Support 3 (S3) | 4.47 | 4.57 | 4.57 | ||
| Support 4 (S4) | 4.50 |
